false 0001821586 0001821586 2024-09-11 2024-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION  13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 11, 2024

 

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

 

Cayman Islands   001-39630   98-1711963
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

Dorfstrasse 29

6300 Zug

Switzerland

(Address of Principal Executive Offices and Zip Code)

 

41 415108022

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share   MLTX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On September 11, 2024, MoonLake Immunotherapeutics (the “Company”) will be posting to its website an investor presentation to be used in the Company’s September 11, 2024 Capital Markets Day event, including information regarding the Company’s financial position, near-term catalysts and publication roadmap. The investor presentation and replays of the webcast will be available on the Company’s website at https://ir.moonlaketx.com.

 

The information in this current report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless specifically so incorporated.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MOONLAKE IMMUNOTHERAPEUTICS
   
Date: September 11, 2024 By: /s/ Matthias Bodenstedt                    
  Name:  Matthias Bodenstedt
  Title: Chief Financial Officer

 

2

 

v3.24.2.u1
Cover
Sep. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 11, 2024
Entity File Number 001-39630
Entity Registrant Name MOONLAKE IMMUNOTHERAPEUTICS
Entity Central Index Key 0001821586
Entity Tax Identification Number 98-1711963
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One Dorfstrasse 29
Entity Address, City or Town Zug
Entity Address, Country CH
Entity Address, Postal Zip Code 6300
City Area Code 41
Local Phone Number 415108022
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A ordinary share, par value $0.0001 per share
Trading Symbol MLTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more MoonLake Immunotherapeut... Charts.
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more MoonLake Immunotherapeut... Charts.